A BILL 
To amend the Internal Revenue Code of 1986 to establish 
an excise tax on certain prescription drugs which have 
been subject to a price spike, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Stop Price Gouging 
4
Act’’. 
5
SEC. 2. IDENTIFICATION OF PRESCRIPTION DRUG PRICE 
6
SPIKES. 
7
(a) DEFINITIONS.—In this section: 
8
22:13 Feb 22, 2019
H1093
2 
•HR 1093 IH
(1) APPLICABLE ENTITY.—The term ‘‘applica-
1
ble entity’’ means the holder of an application ap-
2
proved under subsection (c) or (j) of section 505 of 
3
the Federal Food, Drug, and Cosmetic Act (21 
4
U.S.C. 355) or of a license issued under subsection 
5
(a) or (k) of section 351 of the Public Health Serv-
6
ice Act (42 U.S.C. 262) for a drug described in 
7
paragraph (5)(A). 
8
(2) AVERAGE
MANUFACTURER
PRICE.—The 
9
term ‘‘average manufacturer price’’— 
10
(A) has the same meaning given such term 
11
under section 1927(k)(1) of the Social Security 
12
Act (42 U.S.C. 1396r–8(k)(1)); or 
13
(B) with respect to a drug for which there 
14
is no average manufacturer price as so defined, 
15
such term shall mean the wholesale acquisition 
16
cost of the drug. 
17
(3) COMMERCE.—The term ‘‘commerce’’ has 
18
the meaning given such term in section 4 of the 
19
Federal Trade Commission Act (15 U.S.C. 44). 
20
(4) INSPECTOR GENERAL.—The term ‘‘Inspec-
21
tor General’’ means the Inspector General of the De-
22
partment of Health and Human Services. 
23
(5) PRESCRIPTION DRUG.— 
24
22:13 Feb 22, 2019
H1093
3 
•HR 1093 IH
(A) IN GENERAL.—The term ‘‘prescription 
1
drug’’ means any drug (as defined in section 
2
201(g) of the Federal Food, Drug, and Cos-
3
metic Act (21 U.S.C. 321(g))), including a com-
4
bination product whose primary mode of action 
5
is determined under section 503(g) of such Act 
6
(21 U.S.C. 353(g)) to be that of a drug, and 
7
that— 
8
(i) is subject to section 503(b)(1) of 
9
the Federal Food, Drug, and Cosmetic Act 
10
(21 U.S.C. 353(b)(1)); and 
11
(ii) is covered by a Federal health 
12
care program (as defined in section 
13
1128B(f) of the Social Security Act (42 
14
U.S.C. 1320a–7b(f))). 
15
(B) 
TREATMENT
OF
REFORMULATED 
16
DRUGS.—For purposes of this section, a pre-
17
scription drug with respect to which the Sec-
18
retary of Health and Human Services has ap-
19
proved any minor reformulation that does not 
20
produce a meaningful therapeutic benefit, the 
21
drug that was approved prior to any such refor-
22
mulation and the drug with any such reformu-
23
lation shall be considered one prescription drug. 
24
(6) PRICE SPIKE.— 
25
22:13 Feb 22, 2019
H1093
4 
•HR 1093 IH
(A) IN GENERAL.—The term ‘‘price spike’’ 
1
means an increase in the average manufacturer 
2
price in commerce of a prescription drug for 
3
which the price spike percentage is equal to or 
4
greater than applicable price increase allowance. 
5
(B) 
PRICE
SPIKE
PERCENTAGE.—The 
6
price spike percentage is the percentage (if any) 
7
by which— 
8
(i) the average manufacturer price of 
9
a prescription drug in commerce for the 
10
calendar year; exceeds 
11
(ii) the average manufacturer price of 
12
such prescription drug in commerce for the 
13
calendar year preceding such year. 
14
(C) APPLICABLE PRICE INCREASE ALLOW-
15
ANCE.—The applicable price increase allowance 
16
for any calendar year is the percentage (round-
17
ed to the nearest one-tenth of 1 percent) by 
18
which the C–CPI–U (as defined in section 
19
1(f)(6) of the Internal Revenue Code of 1986) 
20
for that year exceeds the C–CPI–U for the pre-
21
ceding calendar year. 
22
(7) PRICE SPIKE REVENUE.— 
23
(A) IN GENERAL.—The price spike revenue 
24
for any calendar year is an amount equal to— 
25
22:13 Feb 22, 2019
H1093
5 
•HR 1093 IH
(i) the gross price spike revenue, 
1
minus 
2
(ii) the adjustment amount. 
3
(B) GROSS PRICE SPIKE REVENUE.—The 
4
gross price spike revenue for any calendar year 
5
is an amount equal to the product of— 
6
(i) an amount equal to the difference 
7
between clause (i) of paragraph (6)(B) and 
8
clause (ii) of such paragraph; and 
9
(ii) the total number of units of the 
10
prescription drug which were sold in com-
11
merce in such calendar year. 
12
(C) ADJUSTMENT AMOUNT.—The adjust-
13
ment amount is the amount, if any, of the gross 
14
price spike revenue which the Inspector General 
15
has determined is due solely to an increase in 
16
the cost of the inputs necessary to manufacture 
17
the prescription drug subject to the price spike. 
18
(b) SUBMISSION BY PHARMACEUTICAL COMPANIES 
19
OF INFORMATION TO INSPECTOR GENERAL.— 
20
(1) IN GENERAL.—For each prescription drug, 
21
the applicable entity shall submit to the Inspector 
22
General a quarterly report that includes the fol-
23
lowing: 
24
22:13 Feb 22, 2019
H1093
6 
•HR 1093 IH
(A) For each prescription drug of the ap-
1
plicable entity— 
2
(i) the total number of units of the 
3
prescription drug which were sold in com-
4
merce in the preceding calendar quarter; 
5
(ii) the average and median price per 
6
unit of such prescription drug in commerce 
7
in 
the 
preceding 
calendar 
quarter, 
8
disaggregated by month; and 
9
(iii) the gross revenues from sales of 
10
such prescription drug in commerce in the 
11
preceding calendar quarter. 
12
(B) Such information related to increased 
13
input costs or public health considerations as 
14
the applicable entity may wish the Inspector 
15
General to consider in making a determination 
16
under clause (ii) of subsection (c)(2)(B) or an 
17
assessment in clause (iii) of such subsection for 
18
the preceding calendar quarter. 
19
(C) Such information related to any antici-
20
pated increased input costs for the subsequent 
21
calendar quarter as the applicable entity may 
22
wish the Inspector General to consider in mak-
23
ing a determination under clause (ii) of sub-
24
section (c)(2)(B) or an assessment in clause 
25
22:13 Feb 22, 2019
H1093
7 
•HR 1093 IH
(iii) of such subsection for such calendar quar-
1
ter. 
2
(2) PENALTY FOR FAILURE TO SUBMIT.— 
3
(A) IN GENERAL.—An applicable entity de-
4
scribed in paragraph (1) that fails to submit in-
5
formation to the Inspector General regarding a 
6
prescription drug, as required by such para-
7
graph, before the date specified in paragraph 
8
(3) shall be liable for a civil penalty, as deter-
9
mined under subparagraph (B). 
10
(B) AMOUNT OF PENALTY.—The amount 
11
of the civil penalty shall be equal to the product 
12
of— 
13
(i) an amount, as determined appro-
14
priate by the Inspector General, which is— 
15
(I) not less than 0.5 percent of 
16
the gross revenues from sales of the 
17
prescription drug described in sub-
18
paragraph (A) for the preceding cal-
19
endar year, and 
20
(II) not greater than 1 percent of 
21
the gross revenues from sales of such 
22
prescription drug for the preceding 
23
calendar year, and 
24
22:13 Feb 22, 2019
H1093
8 
•HR 1093 IH
(ii) the number of days in the period 
1
between— 
2
(I) the applicable date specified 
3
in paragraph (3), and 
4
(II) the date on which the In-
5
spector General receives the informa-
6
tion described in paragraph (1) from 
7
the applicable entity. 
8
(3) SUBMISSION DEADLINE.—An applicable en-
9
tity shall submit each quarterly report described in 
10
paragraph (1) not later than January 17, April 18, 
11
June 15, and September 15 of each calendar year. 
12
(c) ASSESSMENT BY INSPECTOR GENERAL.— 
13
(1) IN GENERAL.—Not later than the last day 
14
in February of each year, the Inspector General, in 
15
consultation with other relevant Federal agencies 
16
(including the Federal Trade Commission), shall— 
17
(A) complete an assessment of the infor-
18
mation the Inspector General received pursuant 
19
to subsection (b)(1) with respect to sales of pre-
20
scription drugs in the preceding calendar year; 
21
and 
22
(B) in the case of any prescription drug 
23
which satisfies the conditions described in para-
24
graph (1) or (2) of subsection (d), submit a rec-
25
22:13 Feb 22, 2019
H1093
9 
•HR 1093 IH
ommendation to the Secretary of Health and 
1
Human Services that such drug be exempted 
2
from application of the tax imposed under sec-
3
tion 4192 of the Internal Revenue Code of 1986 
4
(as added by section 3 of this Act) for such 
5
year. 
6
(2) ELEMENTS.—The assessment required by 
7
paragraph (1)(A) shall include the following: 
8
(A) Identification of each price spike relat-
9
ing to a prescription drug in the preceding cal-
10
endar year. 
11
(B) For each price spike identified under 
12
subparagraph (A)— 
13
(i) a determination of the price spike 
14
revenue; 
15
(ii) a determination regarding the ac-
16
curacy of the information submitted by the 
17
applicable entity regarding increased input 
18
costs; and 
19
(iii) an assessment of the rationale of 
20
the applicable entity for the price spike. 
21
(d) EXEMPTION OF CERTAIN DRUGS.— 
22
(1) IN GENERAL.—The Secretary of Health and 
23
Human Services, upon recommendation of the In-
24
spector General pursuant to subsection (c)(1)(B), 
25
22:13 Feb 22, 2019
H1093
10 
•HR 1093 IH
may exempt any prescription drug which has been 
1
subject to a price spike during the preceding cal-
2
endar year from application of the tax imposed 
3
under section 4192 of the Internal Revenue Code of 
4
1986 for such year, if the Secretary determines 
5
that— 
6
(A) based on information submitted pursu-
7
ant to subsection (b)(1)(B), a for-cause price 
8
increase exemption should apply; or 
9
(B)(i) the prescription drug which has 
10
been subject to a price spike has an average 
11
manufacturer price of not greater than $10 for 
12
a 30 day supply; and 
13
(ii) such drug is marketed by not less than 
14
3 other holders of applications approved under 
15
subsection (c) or (j) of section 505 of the Fed-
16
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
17
355), where such applications approved under 
18
such subsection (j) use as a reference drug the 
19
drug so approved under such subsection (c). 
20
(2) CLARIFICATION.—In considering, under 
21
paragraph (1)(A), information submitted pursuant 
22
to subsection (b)(1)(B), the Secretary— 
23
22:13 Feb 22, 2019
H1093
11 
•HR 1093 IH
(A) has the discretion to determine that 
1
such information does not warrant a for-cause 
2
price increase exemption; and 
3
(B) shall exclude from such consideration 
4
any information submitted by the applicable en-
5
tity threatening to curtail or limit production of 
6
the prescription drug if the Secretary does not 
7
grant an exemption from the application of the 
8
tax under section 4192 of the Internal Revenue 
9
Code of 1986. 
10
(e) INSPECTOR GENERAL REPORT
TO INTERNAL 
11
REVENUE SERVICE.— 
12
(1) IN GENERAL.—Subject to paragraph (3), 
13
not later than the last day in February of each year, 
14
the Inspector General shall transmit to the Internal 
15
Revenue Service a report on the findings of the In-
16
spector General with respect to the information the 
17
Inspector General received under subsection (b)(1) 
18
with respect to the preceding calendar year and the 
19
assessment carried out by the Inspector General 
20
under subsection (c)(1)(A) with respect to such in-
21
formation. 
22
(2) CONTENTS.—The report transmitted under 
23
paragraph (1) shall include the following: 
24
22:13 Feb 22, 2019
H1093
12 
•HR 1093 IH
(A) The information received under sub-
1
section (b)(1) with respect to the preceding cal-
2
endar year. 
3
(B) The price spikes identified under sub-
4
paragraph (A) of subsection (c)(2). 
5
(C) The price spike revenue determinations 
6
made under subparagraph (B)(i) of such sub-
7
section. 
8
(D) The determinations and assessments 
9
made under clauses (ii) and (iii) of subpara-
10
graph (B) of such subsection. 
11
(3) NOTICE
AND
OPPORTUNITY
FOR
HEAR-
12
ING.— 
13
(A) IN
GENERAL.—No report shall be 
14
transmitted to the Internal Revenue Service 
15
under paragraph (1) in regards to a prescrip-
16
tion drug unless the Inspector General has pro-
17
vided the applicable entity with— 
18
(i) the assessment of such drug under 
19
subsection (c)(1)(A); and 
20
(ii) notice of their right to a hearing 
21
in regards to such assessment. 
22
(B) NOTICE.—The notice required under 
23
subparagraph (A) shall be provided to the ap-
24
plicable entity not later than 30 days after com-
25
22:13 Feb 22, 2019
H1093
13 
•HR 1093 IH
pletion of the assessment under subsection 
1
(c)(1)(A). 
2
(C) REQUEST FOR HEARING.—Subject to 
3
subparagraph (E), an applicable entity may re-
4
quest a hearing before the Secretary of Health 
5
and Human Services not later than 30 days 
6
after the date on which the notice under sub-
7
paragraph (B) is received. 
8
(D) COMPLETION
OF
HEARING.—In the 
9
case of an applicable entity which requests a 
10
hearing pursuant to subparagraph (C), the Sec-
11
retary of Health and Human Services shall, not 
12
later than 12 months after the date on which 
13
the assessment under subsection (c)(1)(A) was 
14
completed by the Inspector General— 
15
(i) make a final determination in re-
16
gards the accuracy of such assessment; 
17
and 
18
(ii) provide the report described in 
19
paragraph (2) to the Internal Revenue 
20
Service. 
21
(E) LIMITATION.—An applicable entity 
22
may request a hearing under subparagraph (C) 
23
with respect to a particular prescription drug 
24
only once within a 5-year period. 
25
22:13 Feb 22, 2019
H1093
14 
•HR 1093 IH
(4) PUBLICATION.— 
1
(A) IN GENERAL.—Not later than the last 
2
day in February of each year, subject to sub-
3
paragraph (B), the Inspector General shall 
4
make the report transmitted under paragraph 
5
(1) available to the public, including on the 
6
Internet website of the Inspector General, sub-
7
ject to subparagraph (B). 
8
(B) 
PROPRIETARY
INFORMATION.—The 
9
Inspector General shall ensure that any infor-
10
mation made public in accordance with sub-
11
paragraph (A) excludes trade secrets and con-
12
fidential commercial information. 
13
(f) NOTIFICATION.—The Secretary of the Treasury, 
14
in conjunction with the Inspector General, shall notify, at 
15
such time and in such manner as the Secretary of the 
16
Treasury shall provide, each applicable entity in regard 
17
to any prescription drug which has been determined to 
18
have been subject to a price spike during the preceding 
19
calendar year and the amount of the tax imposed on such 
20
applicable entity pursuant to section 4192 of the Internal 
21
Revenue Code of 1986. 
22
22:13 Feb 22, 2019
H1093
15 
•HR 1093 IH
SEC. 3. EXCISE TAX ON PRESCRIPTION DRUGS SUBJECT TO 
1
PRICE SPIKES. 
2
(a) IN GENERAL.—Subchapter E of chapter 32 of the 
3
Internal Revenue Code of 1986 is amended by adding at 
4
the end the following new section: 
5
‘‘SEC. 4192. PRESCRIPTION DRUGS SUBJECT TO PRICE 
6
SPIKES. 
7
‘‘(a) IMPOSITION OF TAX.— 
8
‘‘(1) IN GENERAL.—Subject to paragraph (3), 
9
for each taxable prescription drug sold by an appli-
10
cable entity during the calendar year, there is hereby 
11
imposed on such entity a tax equal to the greater 
12
of— 
13
‘‘(A) the annual price spike tax for such 
14
prescription drug, or 
15
‘‘(B) subject to paragraph (2), the cumu-
16
lative price spike tax for such prescription drug. 
17
‘‘(2) LIMITATION.—In the case of a taxable 
18
prescription drug for which the applicable period (as 
19
determined under subsection (c)(2)(E)(i)) is less 
20
than 2 calendar years, the cumulative price spike tax 
21
shall not apply. 
22
‘‘(3) EXEMPTION.—For any calendar year in 
23
which the Secretary of Health and Human Services 
24
has provided an exemption for a taxable prescription 
25
drug pursuant to section 2(d) of the Stop Price 
26
22:13 Feb 22, 2019
H1093
16 
•HR 1093 IH
Gouging Act, the amount of the tax determined 
1
under paragraph (1) for such drug or device for 
2
such calendar year shall be reduced to zero. 
3
‘‘(b) ANNUAL PRICE SPIKE TAX.— 
4
‘‘(1) IN GENERAL.—The amount of the annual 
5
price spike tax shall be equal to the applicable per-
6
centage of the price spike revenue received by the 
7
applicable entity on the sale of the taxable prescrip-
8
tion drug during the calendar year. 
9
‘‘(2) APPLICABLE PERCENTAGE.—For purposes 
10
of paragraph (1), the applicable percentage shall be 
11
equal to— 
12
‘‘(A) in the case of a taxable prescription 
13
drug which has been subject to a price spike 
14
percentage greater than the applicable price in-
15
crease 
allowance 
(as 
defined 
in 
section 
16
2(a)(6)(C) of the Stop Price Gouging Act) but 
17
less than 15 percent, 50 percent, 
18
‘‘(B) in the case of a taxable prescription 
19
drug which has been subject to a price spike 
20
percentage equal to or greater than 15 percent 
21
but less than 20 percent, 75 percent, and 
22
‘‘(C) in the case of a taxable prescription 
23
drug which has been subject to a price spike 
24
22:13 Feb 22, 2019
H1093
17 
•HR 1093 IH
percentage equal to or greater than 20 percent, 
1
100 percent. 
2
‘‘(c) CUMULATIVE PRICE SPIKE TAX.— 
3
‘‘(1) IN GENERAL.—The amount of the cumu-
4
lative price spike tax shall be equal to the applicable 
5
percentage of the cumulative price spike revenue re-
6
ceived by the applicable entity on the sale of the tax-
7
able prescription drug during the calendar year. 
8
‘‘(2) APPLICABLE PERCENTAGE.— 
9
‘‘(A) IN GENERAL.—For purposes of para-
10
graph (1), the applicable percentage shall be 
11
equal to— 
12
‘‘(i) in the case of a taxable prescrip-
13
tion drug which has been subject to a cu-
14
mulative price spike percentage greater 
15
than the cumulative price increase allow-
16
ance but less than the first multi-year per-
17
centage, 50 percent, 
18
‘‘(ii) in the case of a taxable prescrip-
19
tion drug which has been subject to a cu-
20
mulative price spike percentage equal to or 
21
greater than the first multi-year percent-
22
age but less than the second multi-year 
23
percentage, 75 percent, and 
24
22:13 Feb 22, 2019
H1093
18 
•HR 1093 IH
‘‘(iii) in the case of a taxable prescrip-
1
tion drug which has been subject to a cu-
2
mulative price spike percentage equal to or 
3
greater than the second multi-year percent-
4
age, 100 percent. 
5
‘‘(B) CUMULATIVE PRICE SPIKE PERCENT-
6
AGE.—The cumulative price spike percentage is 
7
the percentage (if any) by which— 
8
‘‘(i) the average manufacturer price of 
9
the taxable prescription drug in commerce 
10
for the preceding calendar year, exceeds 
11
‘‘(ii) the average manufacturer price 
12
of such prescription drug in commerce for 
13
the base year. 
14
‘‘(C) CUMULATIVE
PRICE
INCREASE
AL-
15
LOWANCE.—For purposes of clause (i) of sub-
16
paragraph (A), the cumulative price increase al-
17
lowance for any calendar year is the percentage 
18
(rounded to the nearest one-tenth of 1 percent) 
19
by which the C–CPI–U (as defined in section 
20
1(f)(6)) for that year exceeds the C–CPI–U for 
21
the base year. 
22
‘‘(D) MULTI-YEAR
PERCENTAGES.—For 
23
purposes of subparagraph (A), the first multi- 
24
year percentage and second multi-year percent-
25
22:13 Feb 22, 2019
H1093
19 
•HR 1093 IH
age shall be determined in accordance with the 
1
following table: 
2
‘‘Number of years in applicable period 
First multi- 
year per-
centage 
Second 
multi-year 
percentage 
2 years ....................................................................
17.5 
22.5
3 years ....................................................................
20 
25
4 years ....................................................................
22.5 
27.5
5 years ....................................................................
25 
30. 
‘‘(E) APPLICABLE
PERIOD
AND
BASE 
3
YEAR.— 
4
‘‘(i) APPLICABLE PERIOD.—The appli-
5
cable period shall be the lesser of— 
6
‘‘(I) the 5 preceding calendar 
7
years, 
8
‘‘(II) all calendar years beginning 
9
after the date of enactment of this 
10
section, or 
11
‘‘(III) all calendar years in which 
12
the taxable prescription drug was sold 
13
in commerce. 
14
‘‘(ii) BASE
YEAR.—The base year 
15
shall be the calendar year immediately pre-
16
ceding the applicable period. 
17
‘‘(3) CUMULATIVE
PRICE
SPIKE
REVENUE.— 
18
For purposes of paragraph (1), the cumulative price 
19
spike revenue for any taxable prescription drug shall 
20
be an amount equal to— 
21
22:13 Feb 22, 2019
H1093
20 
•HR 1093 IH
‘‘(A) an amount equal to the product of— 
1
‘‘(i) an amount (not less than zero) 
2
equal to— 
3
‘‘(I) the average manufacturer 
4
price of such prescription drug in 
5
commerce for the preceding calendar 
6
year, minus 
7
‘‘(II) the average manufacturer 
8
price of such prescription drug in 
9
commerce for the base year, and 
10
‘‘(ii) the total number of units of such 
11
prescription drug which were sold in com-
12
merce in the preceding calendar year, 
13
minus 
14
‘‘(B) an amount equal to the sum of the 
15
adjustment amounts, if any, determined under 
16
section 2(a)(7)(C) of the Stop Price Gouging 
17
Act for each calendar year during the applicable 
18
period. 
19
‘‘(d) DEFINITIONS.—For purposes of this section— 
20
‘‘(1) 
TAXABLE
PRESCRIPTION
DRUG.—The 
21
term ‘taxable prescription drug’ means a prescrip-
22
tion drug (as defined in section 2(a)(5) of the Stop 
23
Price Gouging Act) which has been identified by the 
24
Inspector General of the Department of Health and 
25
22:13 Feb 22, 2019
H1093
21 
•HR 1093 IH
Human Services, under section 2(c)(2)(A) of such 
1
Act, as being subject to a price spike. 
2
‘‘(2) OTHER TERMS.—The terms ‘applicable en-
3
tity’, ‘average manufacturer price’, ‘price spike’, 
4
‘price spike percentage’, and ‘price spike revenue’ 
5
have the same meaning given such terms under sec-
6
tion 2(a) of the Stop Price Gouging Act.’’. 
7
(b) CLERICAL AMENDMENTS.— 
8
(1) The heading of subchapter E of chapter 32 
9
of the Internal Revenue Code of 1986 is amended by 
10
striking ‘‘Medical Devices’’ and inserting ‘‘Cer-
11
tain Medical Devices and Prescription 
12
Drugs’’. 
13
(2) The table of subchapters for chapter 32 of 
14
such Code is amended by striking the item relating 
15
to subchapter E and inserting the following new 
16
item: 
17
‘‘SUBCHAPTER E. CERTAIN MEDICAL DEVICES AND PRESCRIPTION DRUGS’’. 
(3) The table of sections for subchapter E of 
18
chapter 32 of such Code is amended by adding at 
19
the end the following new item: 
20
‘‘Sec. 4192. Prescription drugs subject to price spikes.’’. 
(c) EFFECTIVE DATE.—The amendments made by 
21
this section shall apply to sales after the date of the enact-
22
ment of this Act. 
23
22:13 Feb 22, 2019
H1093
22 
•HR 1093 IH
SEC. 4. STUDY ON MONOPOLY MEDICAL PRODUCTS. 
1
(a) IN GENERAL.—The Comptroller General of the 
2
United States shall conduct a study that examines— 
3
(1) how drug manufacturers and health plans 
4
(including private insurers, the Medicare program, 
5
and State Medicaid programs) establish initial 
6
launch prices for newly approved drugs; and 
7
(2) alternative methods that have been pro-
8
posed for setting the price of new drugs. 
9
(b) STUDY OF SPECIFIC DRUGS.—As part of the 
10
study described in subsection (a), the Comptroller General 
11
shall examine drug pricing with respect to several drugs 
12
approved within the 5-year period immediately preceding 
13
the date of enactment of this Act and explore potential 
14
alternative approaches to establish new drug prices that 
15
could help make new drugs more affordable, better reflect 
16
the clinical value of such drugs in treating patients, and 
17
maintain incentives for innovation. 
18
(c) FACTORS.—In conducting the study described in 
19
subsection (a), the Comptroller General shall consider— 
20
(1) what factors drug manufacturers and health 
21
plans consider in establishing initial launch prices; 
22
(2) how initial pricing decisions by drug manu-
23
facturers and health plans affect costs and use of 
24
services for patients and public programs such as 
25
the Medicare and Medicaid programs; 
26
22:13 Feb 22, 2019
H1093
23 
•HR 1093 IH
(3) efforts by health plans to limit costs, includ-
1
ing through benefit design or coverage limitations; 
2
(4) how prices change in the first few years fol-
3
lowing a new drug’s launch; and 
4
(5) recommendations manufacturers, health 
5
plans, and other experts have for alternative ap-
6
proaches to establishing new drug prices and the 
7
benefits and challenges associated with such alter-
8
native approaches. 
9
SEC. 5. REVENUES COLLECTED. 
10
There are authorized to be appropriated to the Sec-
11
retary of Health and Human Services such sums as are 
12
equal to any increase in revenue to the Treasury by reason 
13
of the provisions of this Act or the amendments made by 
14
this Act for the purposes of increasing amounts available 
15
to the National Institutes of Health for research and de-
16
velopment of drugs. 
17
Æ 
22:13 Feb 22, 2019
H1093
